| 產品名稱 |
Vaccinia virus |
| 商品貨號 |
B188586 |
| Classification |
Poxviridae, Orthopoxvirus |
| Agent |
Vaccinia virus |
| Strain |
New York City Department of Health Laboratories (Wyeth-calf adapted) |
| Biosafety Level |
2 CDC BMBL recommends vaccination.
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation |
clinical specimen - human |
| Product Format |
frozen |
| Storage Conditions |
-70°C or colder |
| Effect on Host |
Yes, in vitro effects: Cytopathic effects (plaque formation, cell rounding, cell death) CPE characterized by plaque formation, cell ???? ?rounding, and eventual cell destruction. |
| Recommended Host |
Host of Choice: Vero (ATCC CCL-81) |
| Growth Conditions |
Temperature: 37.0°C Duration: 1 - 4 days |
| Name of Depositor |
JH Brown, J Loines |
| Special Collection |
Orthopoxvirus |
| Chain of Custody |
J H Brown Wyeth Laboratories J Loines |
| Source |
clinical specimen - human |
| References |
This virus originated from seed stock supplied to the New York City Health Department in 1856 by J. Loines. In 1876, the New York City Health Department started manufacturing a smallpox vaccine in young bulls. It is this strain that was subsequently passaged by Lederle Laboratories and deposited with the ATCC as VR-325. VR-325 was then adapted to grow in cell culture at the ATCC and designated VR-1536.
ATCC VR-1536 is a tissue culture-adapted strain derived from ATCC VR-325 [no longer available].
Vaccination recommended for laboratory staff manipulating vaccinia, monkeypox, or cowpox viruses [CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 4th ed, 1999 - stock no. 017-040-00547-4].
|
